Quercetin's 20x Bioavailability Problem: Why 1,000 mg of Standard Powder Underperforms 250 mg of Phytosome

Pick up a quercetin bottle on the immune-support, senolytic-stack, or allergy-support shelf. The front label will tell you how much quercetin is in each capsule — 500 mg is the most common number, with 250 mg, 800 mg, and 1,000 mg filling out the rest of the category. The buyer reads the number, assumes bigger is better, and picks the 1,000 mg jug over the 250 mg one because the dollar-per-milligram math looks better on the shelf.

The dollar-per-milligram math is the wrong math. Quercetin's standard-powder oral bioavailability — the fraction of the dose that actually reaches circulation — sits in the 1 to 2 percent range in the published pharmacokinetic literature. That is not a typo. The aglycone form, which is the form in almost every "quercetin" capsule under $25, delivers around 15 mg of circulating quercetin out of a 1,000 mg oral dose, with the remaining 985 mg conjugated at the intestinal wall and the liver, excreted in bile, or passed through the gut unchanged.

The published 20x bioavailability improvement from phytosome delivery — the Indena Quercefit material, specifically — means a 250 mg phytosome capsule puts more quercetin into circulation than a 1,000 mg standard-powder capsule, at a quarter of the labeled mg number. The front-of-label mg comparison is a comparison of ingredient weight, not ingredient effect. The buyer who pays attention to the mg number and ignores the delivery form is overpaying for the dose that does not reach circulation and under-dosing on the dose that does.

Here is the quercetin bioavailability math, the three delivery forms the category actually ships, the studied-dose brackets by form, and the four-question Supplement Facts read.

What quercetin actually does

Quercetin is a flavonol — one of the most abundant polyphenols in the human diet, present at 10 to 30 mg per 100 g in red onions, 4 to 10 mg per 100 g in apples with the skin, 2 to 6 mg per 100 g in capers, and smaller amounts in berries, broccoli, kale, and black and green tea. Typical Western dietary intake of total flavonols runs 20 to 50 mg per day, with quercetin accounting for roughly half of that.

The clinical trial literature on supplemental quercetin anchors on four indications:

• Upper respiratory tract infection in heavily training athletes. The Nieman 2007 and 2010 trials in trained cyclists and runners showed 500 to 1,000 mg per day across 2 to 3 weeks reduced URTI incidence by roughly 36 percent in the quercetin arm versus placebo in the days following heavy exercise bouts.
• Allergic rhinitis and histamine release. Quercetin is a mast cell stabilizer in vitro and has small clinical trial data at 200 to 500 mg per day showing modest reductions in nasal and ocular allergy symptom scores against second-generation antihistamine comparators.
• Blood pressure in hypertensive adults. The Edwards 2007 and subsequent trials at 500 to 750 mg per day for 6 to 12 weeks showed systolic reductions of 3 to 7 mmHg in stage 1 hypertensive subjects, with no meaningful effect in normotensive subjects.
• Senolytic stacking with dasatinib. The Kirkland work at the Mayo Clinic positions quercetin as the fisetin-adjacent senolytic co-administered with dasatinib in the D+Q protocol — specifically 1,000 mg quercetin plus 100 mg dasatinib in intermittent dosing schemes, with the pharmacokinetic exposure driving the senescent-cell clearance effect.

Every one of those indications depends on circulating quercetin reaching a plasma concentration consistent with the mechanism. The concentration depends on the dose and the bioavailability. The bioavailability depends on the delivery form, and the delivery form is the part of the equation the front-of-label mg number does not disclose.

The bioavailability problem

Standard quercetin aglycone — the raw powder milled from Sophora japonica (Japanese pagoda tree) buds, which is where roughly 95 percent of the commercial raw material comes from — has three structural problems that collapse its oral bioavailability:

Low aqueous solubility. Quercetin is lipophilic. The aglycone form is almost insoluble in water and dissolves slowly even in the fat-containing meal context. A tablet or capsule of standard quercetin that passes through the small intestine without dissolving does not deliver quercetin to the enterocyte at all.

Extensive first-pass glucuronidation and sulfation. The small-intestinal enterocyte and the liver carry high UGT and SULT enzyme activity against quercetin. The quercetin that does enter the enterocyte is largely conjugated at the 3-, 7-, or 4′- position before it reaches the hepatic portal vein, and the fraction that reaches the systemic circulation is predominantly as quercetin-3-glucuronide and quercetin-3′-sulfate rather than the free aglycone.

Rapid biliary and renal excretion. Even the circulating conjugates clear quickly — the plasma half-life of quercetin and its primary conjugates runs 11 to 28 hours in the published PK studies, with substantial variability across individuals, and the biliary excretion fraction is high.

The net effect: a 1,000 mg oral dose of standard quercetin aglycone produces a peak plasma concentration of free quercetin in the 150 to 400 nanogram per milliliter range in the Manach 2004 and Erlund 2006 pharmacokinetic series — a concentration one to two orders of magnitude below the in vitro concentrations at which the mast cell stabilization, mitochondrial, and senolytic mechanisms demonstrate activity.

The delivery-form interventions all target one of those three problems.

The three delivery forms the category actually ships

Standard quercetin aglycone powder. Sophora japonica raw material, milled, encapsulated or tableted, nothing else. 1 to 2 percent oral bioavailability in the aglycone-equivalent AUC. This is the format in most products under $25 for a 60- to 120-capsule bottle, and it is the format every published PK trial uses as the "standard quercetin" comparator against which the enhanced delivery forms are measured.

EMIQ (enzymatically modified isoquercetin, isoquercitrin, isoquercetin). Quercetin-3-O-glucoside modified with alpha-glucosyltransferase to attach additional glucose units to the 4′ position. The glucoside bond is cleaved by intestinal lactase-phlorizin hydrolase at the brush border, releasing the aglycone directly into the enterocyte and bypassing the aqueous-solubility bottleneck. The Shimoi 2001 and Olthof 2000 PK data show EMIQ at roughly 10 to 15x the aglycone bioavailability in rising-dose human trials. The branded form most commonly on labels is Alpha-G from the San-Ei Gen material; "isoquercetin" or "quercetin-3-glucoside" on a label without a brand is probably either EMIQ or a lower-grade glucoside variant and the brand mark matters.

Quercetin phytosome (quercetin-phospholipid complex). Quercetin molecularly complexed with phosphatidylcholine from sunflower lecithin, typically at a 1:1 molar ratio, producing a lipid-wrapped quercetin molecule that behaves pharmacokinetically more like a dietary fat than a flavonoid powder. The Riva 2019 crossover PK trial in 12 healthy adults showed 20x AUC advantage for Quercefit phytosome (the Indena branded phytosome material, which is what every published quercetin-phytosome trial uses) versus matched-dose standard quercetin. The Pierro 2021 and subsequent clinical trials at 500 to 1,000 mg per day Quercefit phytosome in COVID-19, exercise-recovery, and allergy indications all built on that PK anchor.

The hierarchy by delivered quercetin per labeled mg: Quercefit phytosome >> EMIQ (isoquercetin) > standard aglycone powder, by roughly 20x and 10x respectively relative to the standard-powder baseline. The hierarchy by cost per labeled mg runs the opposite direction, which is the clean reason the standard-powder format continues to dominate shelf-space despite the bioavailability data.

The studied-dose brackets by form

Standard quercetin aglycone. 500 to 1,000 mg per day in the Nieman URTI trials. 500 to 750 mg per day in the Edwards blood pressure work. 1,000 mg per day in the Kirkland senolytic D+Q protocol. The high end of the standard-powder range sits around 1,000 mg per day. Doses above 1,500 mg per day run into GI tolerability limits (bloating, loose stools) and the plasma AUC plateaus as the solubility bottleneck becomes rate-limiting rather than the dose.

EMIQ / isoquercetin. 150 to 500 mg per day, matched roughly 2:1 against the standard-powder dose on a milligram basis given the 10x AUC advantage. The clinical trial dose range is narrower than for standard powder — most isoquercetin trials sit at 100 to 300 mg per day.

Quercefit phytosome. 250 to 500 mg per day for allergy, exercise recovery, and general antioxidant indications in the published Pierro series. 500 to 1,000 mg per day was used in the Di Pierro COVID-19 symptom-duration trials. On the 20x AUC advantage, 250 mg of Quercefit phytosome is pharmacokinetically comparable to the 5,000 mg dose of standard powder that no label actually delivers.

The practical read for a buyer who wants quercetin exposure in the clinical range: a 500 mg Quercefit phytosome dose per day beats a 1,000 to 1,500 mg standard-powder dose per day at roughly the same monthly cost in the premium end of the shelf, and buys clinical-range plasma exposure that no standard-powder format reliably delivers.

The multi-ingredient blend problem

Quercetin appears as a 50 to 200 mg component in a long list of multi-ingredient formulas: "immune support" blends paired with vitamin C and zinc, "allergy support" blends paired with bromelain and nettle, "senolytic stacks" paired with fisetin and resveratrol, and "cellular health" formulas paired with NAD precursors and polyphenol mixes. Almost all of those blends list the quercetin dose as standard aglycone — the delivery form that will not disclose because the format sells on ingredient-breadth rather than per-ingredient dose.

A 100 mg standard-powder quercetin dose inside an immune-support capsule puts roughly 1 to 2 mg of free quercetin into circulation. The clinical trial literature does not support any mechanism at that circulating level. The ingredient is on the label for the shelf-tag claim ("with quercetin"), not for the dose. The multi-ingredient blend problem is the same problem the proprietary-blends piece names at the full-formula level — the dose that reaches the label is not the dose that reaches the receptor.

The clean exception is a multi-ingredient formula that lists Quercefit phytosome at 150 to 250 mg per serving: at the 20x AUC advantage, the delivered-quercetin equivalent of a 3,000 to 5,000 mg standard-powder dose is in the clinical range, and the multi-ingredient framing works. Those products exist, they are rare, and the label will say "Quercefit" or "Indena quercetin phytosome" explicitly rather than "quercetin" alone.

The four-question Supplement Facts read

1. What delivery form is declared? Quercefit (branded Indena phytosome) or quercetin phospholipid complex is the top tier. EMIQ, isoquercetin, or quercetin-3-glucoside with a brand mark (Alpha-G) is the middle tier. "Quercetin" or "quercetin dihydrate" with no delivery-form disclosure is the standard aglycone format and the bottom tier on bioavailability.

2. What is the per-serving dose, and does it match a studied range for that form? 250 to 500 mg Quercefit phytosome, 150 to 300 mg EMIQ, or 500 to 1,000 mg standard aglycone are the clinical-range brackets. A 50 mg quercetin dose with no form disclosure is a shelf-tag ingredient, not a clinical dose.

3. Is the raw material sourced from Sophora japonica or from a dietary-origin material? Both are legal and functionally equivalent at the molecule level, but a label that is non-specific about raw material is often non-specific about everything else; the better-quality supply chain is the one that discloses.

4. Is the product standalone or stacked into a multi-ingredient blend? A standalone quercetin product at a clinical dose in a disclosed delivery form is the defensible format. A multi-ingredient immune or senolytic blend carrying 50 to 150 mg of unspecified quercetin is a label-claim product, not a dose product. The exception is a multi-ingredient formula that explicitly declares Quercefit or an equivalent phytosome at a clinical dose.

The quercetin category runs on the gap between labeled milligrams and delivered milligrams. The gap is a factor of 20 at the extremes. The four-question read closes the gap at the shelf.